{"organizations": [], "uuid": "aec8364bba939266bac436ddff21af4fa92b5719", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-doses-first/brief-caladrius-biosciences-doses-first-patient-in-mid-stage-critical-limb-ischemia-trial-in-japan-idUSASC09RZA", "country": "US", "domain_rank": 408, "title": "BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-13T14:16:00.000+02:00", "replies_count": 0, "uuid": "aec8364bba939266bac436ddff21af4fa92b5719"}, "author": "", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-doses-first/brief-caladrius-biosciences-doses-first-patient-in-mid-stage-critical-limb-ischemia-trial-in-japan-idUSASC09RZA", "ord_in_thread": 0, "title": "BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}, {"name": "mid-sta", "sentiment": "none"}], "organizations": [{"name": "ge critical limb ischemia trial in japan reuters", "sentiment": "none"}, {"name": "caladrius biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 13, 2018 / 12:17 PM / in 24 minutes BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan Reuters Staff 1 Min Read March 13 (Reuters) - Caladrius Biosciences Inc: * CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-13T14:16:00.000+02:00", "crawled": "2018-03-13T14:43:19.013+02:00", "highlightTitle": ""}